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Abstract. Myc genes are a family of proto-oncogenes whose 
proteins are implicated in the regulation of cell proliferation, 
differentiation and apoptosis, and in regulating the activity of 
genes involved in cell division. The aim of the present study 
was to establish a quantitative description of the expression 
of c-myc and evaluate its relationship with other clinical and 
prognostic factors, as well as to establish a multivariate survival 
prediction model. This is a retrospective study of 68 patients 
diagnosed with oral squamous cell carcinoma (OSCC). We 
constructed a tissue microarray for investigating the expression 
of c-myc by immunohistochemistry. Statistical analyses were 
carried out, and a multivariate model that predicts survival 
was established. The average expression of c-myc was 50.32 
(SD, 26.05) with a range from 6.60 to 99.48; similar for initial 
and advanced tumor stages. Non-smoking patients had higher 
levels of c-myc, showing statistically significant differences 
(Kruskal-Wallis χ2=5.975; P=0.05). We found no statistically 
significant relationship between the quantitative expression 
of c-myc and any other clinical or pathological parameters. 
For each unit of increase of c-myc, the risk increased by 1.15 
(P<0.001; HR, 1.150; 95% CI, 1062-1245). Further study of this 
protein, which may have a significant diagnostic, prognostic 
and therapeutic value is warranted. Its determination can be 
valuable when used together with other markers to assess the 
prognosis of OSCC patients.
Introduction
An oral squamous cell carcinoma (OSCC) is a tumor charac-
terized by multiple multistep genetic alterations, that lead to 
genomic instability and disordered cell growth due to oncogene 
overexpression, subexpression of tumor-suppressor genes and 
other genetic, epigenetic and microRNA alterations (1-5). The 
two most studied oncogenes (dominant) in human solid tumors 
are HER-2/neu and c-myc; while p53 is a tumor-suppressor 
gene involved in almost all human malignancies (6).
Myc genes are a family of proto-oncogenes comprised of 
several members (L-myc, N-myc and c-myc). Myc proteins are 
involved in the regulation of cell proliferation, differentiation 
and apoptosis, and in regulating the activity of genes involved 
in cell division (7). Contrary to classical theory, c-myc is also 
implicated in the control of apoptotic phenomena, possibly 
leading to tumor regression depending on cell type, cell inter-
actions, extracellular matrix and neighboring cells (3,8,9). The 
c-myc protein acts as a transcription factor (10), and ectopic 
expression of this protein is sufficient to induce the progres-
sion of the cell cycle. c-myc is also related to a poor tumor 
prognosis (11-14) as well as the self-renewal of tumor stem 
cells (15-18).
The aim of the present study was to establish a quantita-
tive description of the expression of c-myc and to evaluate its 
relationship with clinical and prognostic factors of OSCC, as 
well as to establish a multivariate survival prediction model.
Materials and methods
Patients. We performed an observational study on a cohort of 
68 patients diagnosed with OSCC who were surgically treated 
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at the Maxillofacial Surgical Unit of the Santiago Teaching 
Hospital (Hospital Clinico Universitario de Santiago), Galicia, 
Spain, between January 2001 and March 2010. The inclusion 
criteria was established according to the surgical treatment 
in compliance with standard procedures, including resection 
of the primary tumor; radical, selective ipsilateral or bilateral 
removal of the regional lymph glands; clinical and patholog-
ical data and the availability of sufficient paraffin-embedded 
material to construct matrices. The clinical and pathological 
variables of each case included age, gender, tumor location, 
tumor stage, smoking habits, drinking habits, recurrence, 
dysplasia in the adjacent margin and vital status (death, by any 
cause) until February 2011.
The sample consisted of 35 men (51.5%) and 33 women 
(48.5%), with an age range from 41 to 96 years (average age, 
67±13.08 years). Tumors were classified according to tumor 
stage at the time of diagnosis in accordance with the 7th 
Edition of the AJCC Cancer Staging Manual by the American 
Joint Committee on Cancer (19). Informed consent for use of 
the samples and data analysis were obtained from each patient 
or caretaker.
Tissue microarray generation. Hematoxylin and eosin-stained 
(H&E) slides were available for review in all cases. Paraffin 
blocks were selected on the basis of the availability of suitable 
formalin-fixed, paraffin-embedded tissue (at least 1-mm thick). 
For characterization of immunohistochemical protein expres-
sion, we constructed five different tissue arrays containing 
representative areas of every tumor. After microscopic evalua-
tion, two areas of each tumor were selected, avoiding necrosis 
and keratin pools. Each tissue array was assembled as previ-
ously described (20). Briefly, two 1.5-mm-diameter cylinders 
of tissue were obtained from representative areas of each 
archival paraffin block and arrayed into a new recipient paraffin 
block with a custom-built precision instrument (Beecher 
Instruments, Silver Spring, MD, USA). These tissues were 
fixed in 4% buffered formalin and were paraffin-embedded 
according to routine procedures. Areas chosen for the cylinder 
core were representative of the tumors. In addition, normal 
tonsil samples were placed adjacent to the tumoral tissues to 
serve as internal controls and to ensure the quality of staining 
in the slides. Initial sections were stained with hematoxylin 
and eosin to verify histopathologic findings.
Immunohistochemistry. Tissue sections (3-µm) from the 
TMA blocks were sectioned and applied to special immu-
nohistochemistry coated slides (Dako, Glostrup, Denmark). 
Immunohistochemical analysis for c-myc was performed 
using a monoclonal antibody (clone 9E11; Novocastra, 
Newcastle, UK) with a concentration 1:100, according to 
the manufacturer's instructions. In brief, antigen retrieval 
was performed for 10 min at 95-99˚C in a water bath, with a 
citrate buffer, pH 9.0. After blocking endogenous peroxidase 
activity, the slides were incubated for 30 min with the c-myc 
antibody. A secondary antibody reagent (polymer-based goat 
anti-mouse antibody fragment conjugated to horseradish 
peroxidase) was applied for 30 min. After applying the chro-
mogenic visualization step using the 3,3'-diaminobenzidine 
chromogen, slides were counterstained with hematoxylin. 
Negative controls were performed using the negative reagent 
control (isotype control antibody). Dysplasia was graded as 
mild, moderate, severe and carcinoma ‘in situ’, according to 
the criteria of the WHO (21).
Evaluation of immunohistochemical results, image digitizing 
and semiquantitative analysis. Cases showing cytoplasmic 
or nuclear positivity for c-myc were considered as positive. 
Slides were digitized using an automated slide scanner 
to produce high-resolution images for visual quantitative 
analysis using an ACIS® III automatic image analysis system 
(Dako). The digital images of the slides were captured by 
the ACIS scanner at low power magnification, and the entire 
slide images were viewed on a monitor. The regions with the 
highest immune percentage of positive cells were selected 
for further automatic scoring. A minimum of three of these 
areas containing only tumor cells was selected manually for 
quantitative evaluation. The final score was the average result 
of the different areas measured. To confirm the accuracy of 
the measurements, selected areas from 10 of the specimens 
were measured three times. 
Statistical analysis. Qualitative variables are expressed 
as frequencies and percentages; quantitative variables are 
expressed as means (standard deviation) and ranges. The χ2 
test or Fisher's exact test was used as required to compare 
the qualitative variables. ANOVA or the Kruskal-Wallis test 
was used to contrast quantitative and qualitative variables. An 
association was considered statistically significant when the 
P-value was ≤0.05. The Kaplan-Meier method/estimator and 
the Cox regression model were used for evaluating survival in 
the study sample.
Initially, we carried out a univariate analysis in which we 
studied the Kaplan-Meier curves of each of the categorical/
qualitative variables to assess if we detected differences in the 
survival between the different groups or levels of these vari-
ables. Subsequently, we adjusted the Cox regression univariate 
models to assess the influence of each of the analyzed variables 
on the survival prognosis. 
A time-dependent multivariate Cox regression mode was 
fitted to jointly evaluate the possible risk factors in terms of 
survival. The recurrence of the patients was considered as 
the time-dependent covariate. The predictive multivariate 
analysis/model was performed using a stepwise procedure in 
terms of the best (the lowest) Akaike Information Criterion 
(AIC) value. The magnitude of the association between covari-
ates and survival was evaluated through hazard ratios (HR), 
together with their corresponding 95% confidence intervals 
(CI). Taking censored survival times into account, the log 
hazard ratios of the Cox model were used as criterion variables 
Y, to construct time-dependent ROC curves (22).
All statistical analyses were conducted using SPSS 
Statistics 17.0 and R 2.15.0 (R Development Core Team, 
2012), using the survival package (for fitting parametric Cox 
regression models), the survivalROC package (for computing 
time-dependent ROC curves) and the censboot function (from 
the bootstrap package) for bootstrapping survival models with 
censored observations. The function stepAIC (from the MASS 
package) was also used for obtaining the multivariate model 
with the best AIC. All these packages are freely available at 
http://www.R-project.org.
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Results
Clinical, anatomical and pathological characteristics of the 
sample. The main clinical characteristics of the 68 patients 
selected for the present study are documented in Table I. 
Tumors were classified into initial stage (stages I and II), which 
accounted for 32 cases (47.8%), and advanced stage (stages III 
and IV), which amounted to 36 cases (52.9%). More men were 
diagnosed in early tumor stages [21 (65.6%)], whereas women 
were found more frequently in advanced stages at the time of 
initial diagnosis [22 (61.1%)] (χ2=4.848, P<0.05).
In terms of the relationship with exposure to tobacco, no 
statistically significant differences in terms of staging at the 
time of diagnosis (χ2=1.227, P=0.541) were noted. In regards to 
alcohol, of the 22 cases exposed to the carcinogen, 16 (72.7%) 
were diagnosed in early stages (χ2=11.338, P<0.01).
The existence of dysplasia in the adjacent margin was 
positive in 42.6% of cases; 34.4% of the tumors in initial 
stages and 50% of the tumors in advanced stages (χ2=2.176, 
P=0.337). The existence of CIS was slightly higher in 
advanced stage tumors [9 (25%)] in contrast to 21.9% found 
in initial cases, although the differences were not statistically 
significant.
c-myc expression in OSCC. Immunohistochemistry showed 
both nuclear and cytoplasmic staining in neoplastic cells, 
while in many cases, the intensity was higher in the cytoplasm 
than that in the nuclei (Fig. 1).
The average expression of c-myc (N=53) was 50.32 (SD, 
26.05) with a range from 6.60 to 99.48; similar for the initial 
stages [mean 50.77 (25.94)] and advanced stages [49.94 
(26.59)] (F=0.013; P=0.909). Women showed higher levels 
[56.47 (25.58)] than men [44.40 (25.56)] although there were 
no statistically significant differences (F=2.951; P=0.877). The 
patients showed virtually similar values of c-myc in terms of 
the degree of tumor differentiation (Kruskal-Wallis χ2=0.062; 
P=0.970). Non-smoking patients had higher levels of c-myc 
[56.15 (5.00)], showing statistically significant differences 
(Kruskal-Wallis χ2=5.975; P=0.05). We found no statistically 
significant relationship between the quantitative expression 
Table I. Clinical characteristics of the OSCC patients, c-myc 
expression and association of variables.
  N=53
 Patients c-myc
Characteristics n (%) mean (SD) P-value
Gender
  Male 35 (51.5) 44.40 (25.56) 0.092
  Female 33 (48.5) 56.47 (25.58)
Exposure to tobacco
  Non-smoker (never) 32 (47.1) 56.15 (5.00) 0.05a
  Former smoker (>10 years) 24 (35.3) 52.43 (5.98)
  Current smoker (≥5 years) 12 (17.6) 32.69 (7.47)
Exposure to alcohol
  Non-drinker 33 (48.5) 56.28 (25.32) 0.206
  Not current drinker 13 (19.1) 52.18 (26.06)
  Current drinker 22 (32.4) 42.03 (26.05)
Primary location
  Buccal mucosa 6 (9) 40.05 (11.45) 0.208
  Gums 17 (25.4) 40.99 (26.53)
  Retromolar trigone 6 (9) 57.80 (32.77)
  Tongue 22 (32.8) 57.13 (24.58)
  Floor of mouth 8 (11.9) 39.77 (24.46)
  Soft palate 8 (11.9) 65.53 (25.38)
T
  T1 21 (30.9) 56.00 (24.26) 0.286
  T2 21 (30.9) 41.87 (25.06)
  T3 4 (5.9) 68.27 (11.00)
  T4 22 (32.4) 50.11 (28.66)
N
  N0 55 (80.9) 49.22 (27.21) 0.462
  N1 7 (10.3) 65.98 (12.44)
  N2 6 (8.8) 47.52 (21.80)
Clinical stage
  I 20 (29.4) 56.01 (24.26) 0.450
  II 12 (17.6) 42.06 (27.70)
  III 9 (13.2) 60.94 (20.13)
  IV 27 (39.7) 47.65 (27.54)
Differentiation
  Good 30 (44.1) 51.06 (5.49) 0.970
  Moderate 30 (44.1) 49.55 (5.24)
  Poor 8 (11.8) 50.45 (13.09)
Recurrence
  Yes 29 (42.6) 50.39 (25.87) 0.979
  No 39 (57.4) 50.19 (1.56)
Dysplasia in margin
  No 38 (55.9) 51.46 (1.29) 0.822
  Low 8 (11.8) 40.55 (2.94)
  Moderate 4 (5.9) 49.35 (20.29)
  Severe 1 (1.5) 68.64
  Carcinoma in situ (CIS) 17 (25) 51.91 (27.91)
aStatistically significant.
Figure 1. A case of oral squamous cell carcinoma showing moderate cyto-
plasmic staining while nuclei are only faintly positive. In this case, expression 
of the antibody was restricted to the lower layers of the tumor nests.
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of c-myc and any other clinical or pathological parameters 
(Table I).
Survival and follow-up analysis. The average follow-up was 
33.5 months (CI, 28.23-40.38). Of the 36 (52.9%) patients who 
died, 24 (66.7%) were in the advanced stage group at the time 
of diagnosis (χ2=5.785, P<0.05). The average survival of the 
sample was 50.52 months (95% CI, 41.07-59.96); according 
to the Kaplan-Meier curve, the cases at the initial stages had 
a higher survival rate (40.72 months) than those in advanced 
stages (28.6 months) and the differences were statistically 
significant (P<0.01) (Fig. 2A). Recurrence occurred in 39 
cases (57.4%) during the follow-up period, regardless of the 
tumor stage at the time of diagnosis (χ2=0.30, P=1.000). We 
detected statistically significant differences in the survival of 
patients with recurrence in contrast with those who did not 
relapse, showing a lower overall survival rate in the recur-
rence group (P<0.01) (Fig. 2B). Survival was also statistically 
significantly reduced in patients with any degree of dysplasia 
in the adjacent margin, in contrast with those who did not 
have dysplasia (P<0.05). 
The Cox univariate regression analysis verified that the 
effect of the value of c-myc alone was not statistically signifi-
cant (P=0.735). In a multivariate Cox analysis, however, the 
multivariate with the lower ACI obtained included the covari-
ates: recurrence, c-myc, gender, location, differentiation, stage, 
size, alcohol consumption, dysplasia in the adjacent margin, 
interaction between c-myc and recurrence, and the interac-
tion between gender and stage (ACI=155.0655). All of the 
variables were statistically significant, except for gender, stage 
and dysplasia in the adjacent margin. Gender and stage were 
not significant, but their relevant interactions were (Table II). 
Using this model, we observed that patients with recurrence 
had a 8303.37-fold higher risk than those without recurrence 
(P<0.01; HR, 8303.37; 95% CI, 34.30-2010000). For each unit 
of increase of c-myc, the risk increased by 1.15 (P<0.001; HR, 
1.150; 95% CI, 1062-1245). Patients with tumors located in the 
gum presented a 278.86-fold higher risk (P<0.001; HR, 278.86; 
95% CI, 13.76-5653), followed by tumors in the tongue, with 
a risk of 16.24 (P<0.05; HR, 16.24; 95% CI, 1.37-193) when 
compared to tumors located in the buccal mucosa. Patients 
with moderate differentiation presented a risk 8.87-fold higher 
(P<0.01; HR, 8.87; 95% CI, 2.01-39.13) than those with well-
differentiated tumors. We found the same results for poorly 
differentiated tumors, which showed a risk 7.48-fold higher 
(P<0.05; HR, 7.48; 95% CI, 1.06-52.73). In patients who were 
former drinkers, the risk decreased by 0.02 (P<0.001; HR, 
0.02; 95% CI, 0.02-0.19).
Temporary AUC showed an approximate mean value of 0.9 
for the follow-up between 35 months and the end of the follow-
up period, which indicates a good discrimination capacity of 
the Cox model (Fig. 3).
Discussion
The influence of c-myc in the carcinogenic process, in general, 
has been previously described in many tumors. In the specific 
case of oral tumors, Goessel et al (23) developed a cellular 
model of oral-esophageal carginogenesis, in which cyclin D1 
Figure 2. Kaplan-Meier survival curves. (A) The patients at initial stages exhibited prolonged survival (40.72 months) when compared with the patients in 
advanced stages (28.6 months). (B) The survival of the recurrence group (Yes) was reduced when compared with the survival of the non-recurrence group (No).
Figure 3. Temporary AUC shows an approximate mean value of 0.9 for the 
follow-up between 35 months and the end of the follow-up period, which 
indicates a good discrimination capacity of the Cox model.
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overexpression and inactivation of p53 lead to the immor-
talization of keratinocytes. Additionally, overexpression of 
ectopic epidermal growth factor receptor (EGFR) and c-myc, 
and the resulting malignant reactivation of telomerase induced 
by EGFR, are sufficient for the malignant transformation of 
oral epithelial cells. Thus, this demonstrated the importance of 
the overexpression of this gene in OSCC (24,25). 
Several studies have analyzed c-myc expression in this type 
of tumor showing different results, with an average positivity 
of 41.28% (2.4-75%) between the different studies (6,26-34). 
The results are extremely contradictory, as well as the varia-
tion in the quantification methods. In the present study we 
effectively developed a quantitative evaluation.
Shah et al (6) found a significantly higher expression in 
T3/T4 tumors in comparison with T1/T2 tumors, although we 
were unable to verify this fact in our research. On the other 
hand, c-myc was correlated with tumor stage and lymphatic 
permeation, while in our study the expression was practically 
the same. Rodrigo et al (35) found no relationship between 
c-myc overexpression and tumor prognosis, similar to 
Hayry et al (33). Baral et al (27) found that tumors with posi-
tive p53 and c-myc were in the advanced stages of the disease 
(poorly differentiated, stage III), while OSCCs in early stages 
did not show positive immonoreactivity for p53 and c-myc.
Eversole and Sapp (36) studied c-myc levels in precan-
cerous lesions and early cancerous lesions, and found that, in 
cases of dysplasia, in situ carcinoma and carcinoma, c-myc 
nuclear tinting was dominant in all the strata harboring 
atypical cells and the degree of tinting increased as the levels 
of atypia were higher. Shah et al (30) described an odds ratio 
(OR) of 6 in the transformation from hyperplasia to dysplasia, 
for c-myc (+) lesions and an OR of 3 for progressions beyond 
early stage carcinoma.
Vora et al (28), in a multivariate analysis, found that 
c-myc multiexpression is a clear indicator of poor prognosis, 
which can be used to evaluate specimens, paired with clinical 
staging, to determine locally advanced tumors. However, 
Tsuzuki et al (37), found no correlation between c-myc and 
5-year survival of patients with oral and oropharangeal carci-
nomas. In our multivariate model, the increase in c-myc levels 
was positively statistically correlated with the risk of death.
The role of c-myc in carcinogenesis has been well 
described; however, its relationship with OSCC and clinical 
and pathological variables of tumors is not entirely clear. 
Thus, further study of this protein, which may have significant 
diagnostic, prognostic and therapeutic value is warranted. The 
determination of c-myc can be valuable when used together 
with other markers to assess the prognosis of OSCC patients.
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